Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.
[PURPOSE] Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), have an increased incidence of second ma
APA
Mishra R, Bagga A, et al. (2025). Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.. JCO oncology practice, OP2500431. https://doi.org/10.1200/OP-25-00431
MLA
Mishra R, et al.. "Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.." JCO oncology practice, 2025, pp. OP2500431.
PMID
41397215
Abstract
[PURPOSE] Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), have an increased incidence of second malignancies. This study describes the patterns, risk factors, and outcomes of second malignancies in MPN with the aim of refining our knowledge.
[METHODS] Using SEER database (2000-2021), we identified patients diagnosed with MPNs. The incidence, patterns, and risk factors of second malignancies including synchronous neoplasms (SYNs, within 6 months of MPN diagnosis), second primary malignancies (SPMs, after 6 months), and secondary AML (s-AML) were assessed separately. Standardized incidence ratios (SIRs) assessed the risk of SPM and s-AML in the MPN cohort compared with the general population.
[RESULTS] Among 43,930 patients with MPN, 1.6% developed SYN, 9.1% SPM, and 1.5% s-AML. Lung, prostate, breast, and colorectal cancers were most frequent solid SPMs, with lung cancer risk particularly higher in PV (SIR, 1.47) and ET (SIR, 1.23). Older age at MPN diagnosis (age 40-59 years, odds ratio [OR; 95% CI], 3.82 [3.09 to 4.78]; age 60-84 years, OR [95% CI], 6.19 [5.02 to 7.7]; ref: 18-39 years) and male sex ( female, OR [95% CI], 1.37 [1.28 to 1.46]) were associated with a higher risk of SPM. The overall SPM risk was higher than that of the general population (SIR [95% CI], 1.14 [1.11 to 1.18]; < .05), with a particularly higher risk of hematologic SPMs (SIR [95% CI], 1.70 [1.55 to 1.85]; < .05) and s-AML (SIR [95% CI], 19.36 [17.92 to 20.88]; < .05). SPM development was associated with reduced median survival (125 184 months, < .0001) after MPN diagnosis. s-AML progression reduced the median survival to 80, 82, and 43 months for patients with PV, ET, and PMF, respectively.
[CONCLUSION] Patients with MPN have a higher risk of second malignancies, compared with the general population, which is associated with reduced survival. This necessitates age-appropriate cancer screening, dermatologic examinations, and long-term surveillance. Further studies are warranted to delineate the underlying factors contributing to this risk.
[METHODS] Using SEER database (2000-2021), we identified patients diagnosed with MPNs. The incidence, patterns, and risk factors of second malignancies including synchronous neoplasms (SYNs, within 6 months of MPN diagnosis), second primary malignancies (SPMs, after 6 months), and secondary AML (s-AML) were assessed separately. Standardized incidence ratios (SIRs) assessed the risk of SPM and s-AML in the MPN cohort compared with the general population.
[RESULTS] Among 43,930 patients with MPN, 1.6% developed SYN, 9.1% SPM, and 1.5% s-AML. Lung, prostate, breast, and colorectal cancers were most frequent solid SPMs, with lung cancer risk particularly higher in PV (SIR, 1.47) and ET (SIR, 1.23). Older age at MPN diagnosis (age 40-59 years, odds ratio [OR; 95% CI], 3.82 [3.09 to 4.78]; age 60-84 years, OR [95% CI], 6.19 [5.02 to 7.7]; ref: 18-39 years) and male sex ( female, OR [95% CI], 1.37 [1.28 to 1.46]) were associated with a higher risk of SPM. The overall SPM risk was higher than that of the general population (SIR [95% CI], 1.14 [1.11 to 1.18]; < .05), with a particularly higher risk of hematologic SPMs (SIR [95% CI], 1.70 [1.55 to 1.85]; < .05) and s-AML (SIR [95% CI], 19.36 [17.92 to 20.88]; < .05). SPM development was associated with reduced median survival (125 184 months, < .0001) after MPN diagnosis. s-AML progression reduced the median survival to 80, 82, and 43 months for patients with PV, ET, and PMF, respectively.
[CONCLUSION] Patients with MPN have a higher risk of second malignancies, compared with the general population, which is associated with reduced survival. This necessitates age-appropriate cancer screening, dermatologic examinations, and long-term surveillance. Further studies are warranted to delineate the underlying factors contributing to this risk.
같은 제1저자의 인용 많은 논문 (4)
- Live biotherapeutics in cancer therapy.
- Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer.
- Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial.
- Barriers and facilitators in oral hygiene maintenance in children undergoing chemotherapy for acute lymphoblastic leukemia: a qualitative investigation.